Tumour cell blebbing and extracellular vesicle shedding: key role of matrikines and ribosomal protein SA.


Journal

British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635

Informations de publication

Date de publication:
02 2019
Historique:
received: 30 05 2018
accepted: 20 12 2018
revised: 06 12 2018
pubmed: 12 2 2019
medline: 31 10 2019
entrez: 12 2 2019
Statut: ppublish

Résumé

Carcinogenesis occurs in elastin-rich tissues and leads to local inflammation and elastolytic proteinase release. This contributes to bioactive matrix fragment (Matrikine) accumulation like elastin degradation products (EDP) stimulating tumour cell invasive and metastatic properties. We previously demonstrate that EDPs exert protumoural activities through Hsp90 secretion to stabilised extracellular proteinases. EDP influence on cancer cell blebbing and extracellular vesicle shedding were examined with a videomicroscope coupled with confocal Yokogawa spinning disk, by transmission electron microscopy, scanning electron microscopy and confocal microscopy. The ribosomal protein SA (RPSA) elastin receptor was identified after affinity chromatography by western blotting and cell immunolocalisation. mRNA expression was studied using real-time PCR. SiRNA were used to confirm the essential role of RPSA. We demonstrate that extracellular matrix degradation products like EDPs induce tumour amoeboid phenotype with cell membrane blebbing and shedding of extracellular vesicle containing Hsp90 and proteinases in the extracellular space. EDPs influence intracellular calcium influx and cytoskeleton reorganisation. Among matrikines, VGVAPG and AGVPGLGVG peptides reproduced EDP effects through RPSA binding. Our data suggests that matrikines induce cancer cell blebbing and extracellular vesicle release through RPSA binding, favouring dissemination, cell-to-cell communication and growth of cancer cells in metastatic sites.

Sections du résumé

BACKGROUND
Carcinogenesis occurs in elastin-rich tissues and leads to local inflammation and elastolytic proteinase release. This contributes to bioactive matrix fragment (Matrikine) accumulation like elastin degradation products (EDP) stimulating tumour cell invasive and metastatic properties. We previously demonstrate that EDPs exert protumoural activities through Hsp90 secretion to stabilised extracellular proteinases.
METHODS
EDP influence on cancer cell blebbing and extracellular vesicle shedding were examined with a videomicroscope coupled with confocal Yokogawa spinning disk, by transmission electron microscopy, scanning electron microscopy and confocal microscopy. The ribosomal protein SA (RPSA) elastin receptor was identified after affinity chromatography by western blotting and cell immunolocalisation. mRNA expression was studied using real-time PCR. SiRNA were used to confirm the essential role of RPSA.
RESULTS
We demonstrate that extracellular matrix degradation products like EDPs induce tumour amoeboid phenotype with cell membrane blebbing and shedding of extracellular vesicle containing Hsp90 and proteinases in the extracellular space. EDPs influence intracellular calcium influx and cytoskeleton reorganisation. Among matrikines, VGVAPG and AGVPGLGVG peptides reproduced EDP effects through RPSA binding.
CONCLUSIONS
Our data suggests that matrikines induce cancer cell blebbing and extracellular vesicle release through RPSA binding, favouring dissemination, cell-to-cell communication and growth of cancer cells in metastatic sites.

Identifiants

pubmed: 30739912
doi: 10.1038/s41416-019-0382-0
pii: 10.1038/s41416-019-0382-0
pmc: PMC6461924
doi:

Substances chimiques

Amides 0
Extracellular Matrix Proteins 0
HSP90 Heat-Shock Proteins 0
Heterocyclic Compounds, 4 or More Rings 0
Peptide Fragments 0
Pyridines 0
RPSA protein, human 0
Receptors, Laminin 0
Ribosomal Proteins 0
Y 27632 138381-45-0
blebbistatin 20WC4J7CQ6
Elastin 9007-58-3
ROCK1 protein, human EC 2.7.11.1
rho-Associated Kinases EC 2.7.11.1
Calcium SY7Q814VUP

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

453-465

Références

Semin Cancer Biol. 2002 Jun;12(3):209-17
pubmed: 12083851
J Cell Biochem. 2018 Sep;119(9):7350-7362
pubmed: 29768689
Clin Exp Metastasis. 1998 Aug;16(6):489-500
pubmed: 9872597
J Am Soc Nephrol. 2016 Jan;27(1):12-26
pubmed: 26251351
Crit Rev Oncol Hematol. 2004 Mar;49(3):199-202
pubmed: 15036260
J Biol Chem. 2008 Jan 25;283(4):2031-41
pubmed: 18056992
Exp Cell Res. 1961;Suppl 8:154-73
pubmed: 13775553
Annu Rev Cell Dev Biol. 2009;25:567-95
pubmed: 19575644
J Biol Chem. 1989 Oct 5;264(28):16652-7
pubmed: 2550450
Clin Physiol Biochem. 1990;8(6):273-82
pubmed: 2132161
J Biol Chem. 2009 Apr 3;284(14):9280-9
pubmed: 19179340
J Cell Biol. 1998 Feb 9;140(3):647-57
pubmed: 9456324
Biochem Biophys Res Commun. 1991 May 31;177(1):177-83
pubmed: 1828340
J Biol Chem. 2009 Oct 16;284(42):28616-23
pubmed: 19617625
PLoS One. 2015 Oct 01;10(10):e0139584
pubmed: 26427016
J Biol Chem. 2014 Jan 17;289(3):1467-77
pubmed: 24293364
J Natl Cancer Inst. 1993 Mar 3;85(5):398-402
pubmed: 8433393
Am J Pathol. 2004 May;164(5):1807-15
pubmed: 15111327
Mod Pathol. 1991 Mar;4(2):239-46
pubmed: 1646457
Science. 1988 Mar 25;239(4847):1539-41
pubmed: 2832941
Br J Cancer. 2014 Jul 8;111(1):139-48
pubmed: 24874477
Nat Cell Biol. 2004 Jun;6(6):507-14
pubmed: 15146192
Curr Biol. 2011 Dec 6;21(23):R940-1
pubmed: 22153157
Nat Cell Biol. 2001 Apr;3(4):E91-3
pubmed: 11283625
Cancer Res. 2017 May 1;77(9):2306-2317
pubmed: 28202510
J Biol Chem. 2002 Nov 22;277(47):44854-63
pubmed: 12244048
Oncotarget. 2018 Apr 3;9(25):17839-17857
pubmed: 29707150
J Biol Chem. 1997 Jul 4;272(27):17216-22
pubmed: 9202045
Glia. 1999 Jan 15;25(2):179-89
pubmed: 9890632
Arterioscler Thromb Vasc Biol. 2011 Jan;31(1):15-26
pubmed: 21160064
J Cell Biol. 2003 Jan 20;160(2):267-77
pubmed: 12527751
Eur Urol. 2001 Nov;40(5):495-503
pubmed: 11752855
Pathobiology. 2013;80(1):24-31
pubmed: 22832241
J Cell Biol. 1998 Apr 20;141(2):409-18
pubmed: 9548719
PLoS One. 2011;6(9):e25332
pubmed: 21966499
Thorax. 1992 Nov;47(11):937-42
pubmed: 1465752
Genes Dev. 2007 Jun 15;21(12):1478-83
pubmed: 17575049
Oncology. 1998 Sep-Oct;55(5):456-60
pubmed: 9732225
Clin Exp Metastasis. 2012 Jun;29(5):511-22
pubmed: 22434583
Clin Cancer Res. 1997 Feb;3(2):227-31
pubmed: 9815677
Ital J Anat Embryol. 2005;110(2 Suppl 1):127-33
pubmed: 16101030
J Cell Sci. 2010 May 15;123(Pt 10):1603-11
pubmed: 20445011
J Cell Biochem. 1999 Jun 15;73(4):488-99
pubmed: 10733343
Nat Rev Mol Cell Biol. 2008 Sep;9(9):730-6
pubmed: 18628785
Semin Immunopathol. 2011 Sep;33(5):455-67
pubmed: 21318413
J Mol Biol. 2008 May 2;378(3):530-9
pubmed: 18387633
J Cell Biol. 2017 Jan 2;216(1):93-100
pubmed: 27998990
J Biol Chem. 2010 Dec 17;285(51):40039-49
pubmed: 20937816
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18581-6
pubmed: 19846787
Biochim Biophys Acta. 2002 Aug 19;1591(1-3):129-138
pubmed: 12183063
Biol Rev Camb Philos Soc. 2016 May;91(2):288-310
pubmed: 25630983
Mol Biol Cell. 2003 Jul;14(7):2655-64
pubmed: 12857854
Nat Cell Biol. 2003 Aug;5(8):711-9
pubmed: 12844144
J Cell Biol. 2006 Nov 6;175(3):477-90
pubmed: 17088428
Am J Physiol. 1999 Jul;277(1):C20-8
pubmed: 10409104
Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):101-17
pubmed: 15000152
J Biol Chem. 2001 Feb 16;276(7):5222-7
pubmed: 11084020
Biochem J. 1996 Sep 15;318 ( Pt 3):955-8
pubmed: 8836143
PLoS One. 2013 Jun 18;8(6):e66297
pubmed: 23823499
Semin Cell Dev Biol. 2015 Apr;40:41-51
pubmed: 25721812
Trends Cell Biol. 1995 Nov;5(11):419-23
pubmed: 14732046
J Cell Biol. 2008 Jun 16;181(6):879-84
pubmed: 18541702
Am Rev Respir Dis. 1989 Nov;140(5):1458-62
pubmed: 2817613

Auteurs

Bertrand Brassart (B)

Université de Reims Champagne Ardenne, SFR CAP-Santé (FED 4231), Laboratoire de Biochimie Médicale et Biologie Moléculaire, Reims, France. bertrand.brassart@univ-reims.fr.
CNRS UMR 7369, Matrice Extracellulaire et Dynamique Cellulaire - MEDyC, Reims, France. bertrand.brassart@univ-reims.fr.

Jordan Da Silva (J)

Université de Reims Champagne Ardenne, SFR CAP-Santé (FED 4231), Laboratoire de Biochimie Médicale et Biologie Moléculaire, Reims, France.
CNRS UMR 7369, Matrice Extracellulaire et Dynamique Cellulaire - MEDyC, Reims, France.

Mélissa Donet (M)

Université de Reims Champagne Ardenne, SFR CAP-Santé (FED 4231), Laboratoire de Biochimie Médicale et Biologie Moléculaire, Reims, France.
CNRS UMR 7369, Matrice Extracellulaire et Dynamique Cellulaire - MEDyC, Reims, France.

Emeline Seurat (E)

Université de Reims Champagne Ardenne, SFR CAP-Santé (FED 4231), Laboratoire de Biochimie Médicale et Biologie Moléculaire, Reims, France.
CNRS UMR 7369, Matrice Extracellulaire et Dynamique Cellulaire - MEDyC, Reims, France.

Frédéric Hague (F)

Université de Picardie Jules Verne, SFR CAP-Santé (FED 4231), Laboratoire de Physiologie Cellulaire et Moléculaire, EA 4667, Amiens, France.

Christine Terryn (C)

Plate-forme Imagerie Cellulaire et Tissulaire, Université de Reims Champagne-Ardenne, Reims, France.

Fréderic Velard (F)

Biomatériaux & inflammation en site osseux, EA 4691, SFR CAP-Santé (FED 4231), Université de Reims-Champagne-Ardenne, Reims, France.

Jean Michel (J)

Laboratoire de Recherche en Nanosciences, EA 4682, SFR CAP-Santé (FED 4231), Université de Reims-Champagne-Ardenne, Reims, France.

Halima Ouadid-Ahidouch (H)

Université de Picardie Jules Verne, SFR CAP-Santé (FED 4231), Laboratoire de Physiologie Cellulaire et Moléculaire, EA 4667, Amiens, France.

Jean-Claude Monboisse (JC)

Université de Reims Champagne Ardenne, SFR CAP-Santé (FED 4231), Laboratoire de Biochimie Médicale et Biologie Moléculaire, Reims, France.
CNRS UMR 7369, Matrice Extracellulaire et Dynamique Cellulaire - MEDyC, Reims, France.
CHU Reims, Laboratoire Central de Biochimie, Reims, France.

Aleksander Hinek (A)

Physiology & Experimental Medicine Program, Hospital for Sick Children, Toronto, ON, Canada.
Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

François-Xavier Maquart (FX)

Université de Reims Champagne Ardenne, SFR CAP-Santé (FED 4231), Laboratoire de Biochimie Médicale et Biologie Moléculaire, Reims, France.
CNRS UMR 7369, Matrice Extracellulaire et Dynamique Cellulaire - MEDyC, Reims, France.
CHU Reims, Laboratoire Central de Biochimie, Reims, France.

Laurent Ramont (L)

Université de Reims Champagne Ardenne, SFR CAP-Santé (FED 4231), Laboratoire de Biochimie Médicale et Biologie Moléculaire, Reims, France.
CNRS UMR 7369, Matrice Extracellulaire et Dynamique Cellulaire - MEDyC, Reims, France.
CHU Reims, Laboratoire Central de Biochimie, Reims, France.

Sylvie Brassart-Pasco (S)

Université de Reims Champagne Ardenne, SFR CAP-Santé (FED 4231), Laboratoire de Biochimie Médicale et Biologie Moléculaire, Reims, France.
CNRS UMR 7369, Matrice Extracellulaire et Dynamique Cellulaire - MEDyC, Reims, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH